Elite Pharmaceuticals Inc (ELTP)

[no2koolaid]

It is merely another form of buyer preferences that guide all market decisions. If we extend that and consider the liability prescribers will face when making a decision to prescribe non-ADFs and ADFs, the question the prescribers will have to answer in a court of law is not hard to fathom..."Please tell the court, in your own words, why you chose to prescribe a non-ADF opioid when there are effective ADFs you could have prescribed and that may well have prevented this tragedy?"

Not sure too many people want to be in a position to have to answer that question. ADFs WILL BE the prescription of choice.

So, it matters little what the FDA intends, the external forces at play outside their purview will influence the decision. Elite understands this market dynamic will benefit them; as do any other potential competitor in the market. It is about market dynamics and new product development...creative destruction, as we know it.